期刊文献+

ⅢA-N_2期非小细胞肺癌手术患者的预后影响因素分析 被引量:5

下载PDF
导出
摘要 目的分析ⅢA-N2期非小细胞肺癌(NSCLC)患者以外科治疗为主的综合疗效及预后影响因素。方法回顾性分析312例ⅢA-N2期NSCLC手术患者的临床资料,并对其预后及影响预后的临床病理因素和淋巴结因素进行分析。结果患者术后总体5年生存率25.6%。单因素分析显示,影响预后的临床病理因素为气管镜活检是否阳性、肿瘤直径、T分期、术后是否放疗(P<0.05或<0.01);影响预后的淋巴结因素为N2淋巴结转移数、隆突下淋巴结是否阳性和淋巴结转移组数(P均<0.05)。Cox回归多因素分析提示,淋巴结转移组数、肿瘤直径、气管镜活检是否阳性和术后放疗是ⅢA-N2期NSCLC独立的预后影响因素(P<0.05或<0.01)。结论ⅢA-N2期NSCLC患者预后差,淋巴结转移组数、肿瘤直径、气管镜活检是否阳性及术后放疗均是其独立的预后影响因素。术中行系统性纵隔淋巴结清扫术且转移淋巴结数<4个、隆突下淋巴结阴性、单组转移者预后较好,应积极手术治疗。
出处 《山东医药》 CAS 2012年第21期59-61,共3页 Shandong Medical Journal
  • 相关文献

参考文献10

  • 1Hayat MJ, Howlader N, Reichman ME, et al. Cancer statistics, trends, and multiple primary cancer analysis from the surveillance, epidemiology, and end results (SEER) program [ J ]. Oncologist, 2007,12( 1 ) :20-37.
  • 2Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: Globocan 2000[J]. Int J Cancer, 2001,94(2) :153-156.
  • 3Thomas PA. Stage III A N2 non-small-cell lung cancer: current con- troversies in combined-modality therapy [ J ]. Eur J Cardiothorac Surg, 2009,36 ( 3 ) :431-432.
  • 4Casali C, Stefani A, Natali P, et al. Prognostic factors in surgically resected N2 NSCLC : the importance of patterns of mediastinal lymph nodes metastases [ J ]. Eur J Cardiothorac Surg, 2005,28 ( 1 ) : 33-.
  • 5Makoto Saito, Harubumi Kato. Prognostic factors in patients with pathological and N2 NSCLC [ J ]. Ann Thorac Cardiovasc Surg, 2008,14( 1 ) :1-2.
  • 6王思愚,吴一龙,戎铁华,黄植藩,区伟.Ⅲ期N2非小细胞肺癌的外科治疗[J].中华肿瘤杂志,2002,24(6):605-607. 被引量:24
  • 7魏丽娟,王虹,王连庆.ⅢA-N2期非小细胞肺癌预后相关因素分析[J].山东医药,2010,50(22):57-58. 被引量:4
  • 8Kim K J, Ahn YC, Limdo H, et al. Analyses on prognostic factors following trimodality therapy for stage ~I A non-small cell lung canc- er[J]. Lung Cancer, 2007,55(3) : 329-336.
  • 9Keller SM, Adak S, Wagner H, et al. A randomized trial of postop- erative adjuvant therapy in patients with completely resected stage I1 or HI A non-small cell lung cancer [ J ]. N Engl J Med, 2000,343 (17) :1217-1222.
  • 10Robinson LA, Ruckdeschel JC, Wagner H Jr, et al. Treatment of non-small cell lung cancer-stage A: ACCP evidence-based clini- cal practice guidelines(2nd edition) [J]. Chest, 2007,132(Suppl 3 ) :243S-265 S.

二级参考文献12

  • 1金波,沈洁,纪灏,廖美琳,韩宝惠,周允中,陈文虎.手术切除的ⅢA期-N2非小细胞肺癌预后因素分析[J].中国癌症杂志,2004,14(3):258-261. 被引量:7
  • 2Goya T,Asamura H,Yoshimura H,et al.Prognosis of 6644 resected non-smal cell lung cancers in Japan[J].Lung Cancer,2005,50(2):227-234.
  • 3Thomas PA.Stage IIIA N2 non-small-cell lung cancer:current controversies in combined-modality therapy[J].Eur J Cardiothorac Surg,2009,36(3):431-432.
  • 4Kappers I,van Sandick JW,Burgers SA,et al.Surgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer:why pneumonectomy should be avoided[J].Lung Cancer,2010,68(2):222-227.
  • 5Douillard JY,Rosell R,De Lena M,et al.Adjuvant vinorelbine plus cisp latin versus observation in patients with comp letely resected stage ⅠB-ⅢA non-small cell lung cancer[J].Lancet Oncol,2006,7(9):719-727.
  • 6Alam N,Darling G,Evans WK,et al.Adjuvant chemotherapy for comp letely resected non-small cell lung cancer[J].Oncol Hematol,2006,58(2):146-155.
  • 7Spira A,Ettinger DS.Multidisciplinary management of lung Cancer[J].N Engl J Med,2004,350(4):379-392.
  • 8林勇斌,梁颖,林鹏,朱志华,张旭,傅剑华,张兰军,龙浩,王思愚,曾灿光,戎铁华.288例手术切除的IIIA-N2非小细胞肺癌患者的生存分析[J].中国肺癌杂志,2009,12(6):587-591. 被引量:4
  • 9吴一龙,黄植蕃,戎铁华,杨名添.基于97分期的非小细胞肺癌术后分期和生存研究[J].中华肿瘤杂志,1999,21(5):363-365. 被引量:75
  • 10吴一龙,王思愚,黄植蕃,区伟,杨学宁,余辉.Ⅰ~ⅢA期非小细胞肺癌淋巴结清扫范围的前瞻性研究[J].中华肿瘤杂志,2001,23(1):43-45. 被引量:69

共引文献26

同被引文献37

  • 1姜伟.核因子-κB/p65和环氧化酶-2表达对非小细胞肺癌患者预后的影响[J].中国老年学杂志,2014,34(12):3287-3290. 被引量:3
  • 2De Craene S,Sunnont V,van Meerbeeck JP. Adjuvant or neoadjuvant chemotherapy in minimal N2 stage m A nonsmall cell lung cancer [J]. Current Opinion in Oncology,2010,22 (2) :102-111.
  • 3Singh T,Katiyar SK. Honokiol Inhibits Non-Small Cell Lung Cancer Cell Migration by Targeting PGE2 -Mediated Activation of β-Catenin Signaling [J]. PLoS One, 2013,8 (4) : e60749.
  • 4Baba T,Uramoto H,Takenaka M,et al. Prognostic factors before and after recurrence of resected non-small cell lung cancer [J]. Respir Investig, 2012,50 (4) : 151-156.
  • 5Dellamore A,Monteverde M, Caroli G, et al. Surgical results and survival of older patients with unsuspected N2 (stage Ⅲ A)non-small cell lung cancer [J]. G Chir,2013,34 (3):53- 58.
  • 6Ettinger DS,Akerley W,Borghaei H. Non-small cell lung cancer [J]. J Natl Compr Canc Netw,2012,10 (10) : 1236- 1271.
  • 7Prenzel KL,Bollschweiler E,Schrder W,et al. Prognostic relevance of skip metastases in esophageal cancer [J]. Ann Thorac Surg, 2010,90 (5) : 1662-1667.
  • 8Hanagiri T,Takenaka M, Oka S,et al. Clinical significance in the number of involved lymph nodes in patients that underwent surgery for pathological stage Ⅲ-N2 non-small cell lung cancer [J]. J Cardiothorac Snrg,2011,6:144.
  • 9Bartheld MB,Versteegh MI, Braun J,et al. Transesophageal ultrasound-guided fine-needle aspiration for the mediastinal restaging of non-small cell lung cancer [J]. J Thorac Oncol, 2011,6(9) : 1510-1515.
  • 10Ji Z,Bi N,Wang J,et al.Risk factors for brain metastases in locally advanced non-small cell lung cancer with definitive chest radiation[J].International Journal of Radiation Oncology,Biology,Physics,2014,89(2):330-337.

引证文献5

二级引证文献22

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部